Author’s response to reviews

Title: Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility

Authors:

Hui Deng (huideng_ny@163.com)
Jianjian Wang (wangjj_hrb@163.com)
Xiaotong Kong (xiaotongk_23@163.com)
Huixue Zhang (huixue81@163.com)
Tianfeng Wang (wg33tianfeng@163.com)
Wenqi Tian (wqtian665@163.com)
Tingting Yi (yting2g@163.com)
Lihua Wang (lihua_wlh@163.com)

Version: 2 Date: 23 Sep 2019

Author’s response to reviews:

Technical Comments:
1. Please italicize the gene symbol throughout the manuscript.
   Answer: Thank you very much for your suggestion, we have italicize all the gene symbol throughout the manuscript.
   Additionally, please replace Χ² with χ²
   Answer: χ² have been replaced.
2. Please format your abstract under the following headings:
   • Background
   • Methods
   • Results
   • Conclusions
   • Keywords
   Answer: Thank you very much for your suggestion, we have formatted our abstract.
3. Please change the section heading “Introduction” to “Background”.
   Answer: Background heading have been revised.
4. Please change the section heading “Materials and Methods” to “Methods”.
   Answer: Methods have been changed.
5. Please add a “Conclusions” section after the “Discussion”. This should state clearly the main
conclusions of the research article and give a clear explanation of their importance and relevance.
Answer: Conclusion section have been added.

6. Please note that all manuscripts must contain all the following sections under the heading 'Declarations'. The Declarations should follow the Conclusions section, and be before the References.
Answer: we have checked and added all the declarations.

• Abbreviations
• Ethics approval and consent to participate
• Consent for publication
• Availability of data and material
• Competing interests
• Funding
• Authors' contributions
• Acknowledgements

7. Please confirm whether your study was submitted to and approved by your institutional ethics committee and include a statement to this effect in your “Ethics approval and consent to participate” section. Please also ensure that the full name of your ethics committee is included in this statement. If the need for ethics approval was waived by an IRB or is deemed unnecessary according to national regulations, please clearly state this, including the name of the IRB or a reference to the relevant legislation.
Answer: we have added the Ethics approval information.

8. Please confirm whether informed consent, written or verbal, was obtained from all participants and clearly state this in your "Ethics and Consent to Participate" section. If verbal, please state the reason and whether the ethics committee approved this procedure. If the need for consent was waived by an ethics committee or is deemed unnecessary according to national regulations, please clearly state this, including the name of the committee or a reference to the relevant legislation.
Answer: we have added the Ethics approval and consent to participate information.

9. As many abbreviations are used throughout the paper, we ask that you include a list of abbreviations (before the declarations section) for reference and ease of reading. All abbreviations should still be defined in the text at first use.
Answer: we have added the abbreviations.

10. The Availability of data and materials section refers to the raw data used in your study and presenting tables and figures is not sufficient to state that all data is contained within the manuscript and additional files. Please only use this statement if you have indeed provided all raw data on which your study is based. We strongly encourage all authors to share their raw data, either by providing it in a supplementary file or depositing it in a public repository and providing the details on how to access it in this section. If you do not wish to share your data, please clearly state this in this section along with a justification. Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):
Answer: we have added Availability of data and material.

• The datasets generated and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
• The datasets used and/or analysed during the current study available from the corresponding author
on reasonable request.
- The datasets generated and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
- The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].

11. Please represent authors' names using their full initials, not their full name, in the Authors’ Contributions section. If there are any duplicated initials, please differentiate them to make it clear that the initials refer to separate authors.
   Answer: we have revised the Authors’ Contributions section

12. Please include a statement in the Authors’ contributions section to the effect that all authors have read and approved the manuscript, and ensure that this is the case.
   Answer: we have revised added the statement.

13. In the “Funding” section of your declarations, please clarify the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
   Answer: we have revised the funding information.

14. Please amend the statement in the "Consent for publication" section, as this refers to consent obtained to publish potentially-identifying information (of patients/participants). If your manuscript does not contain any individual person’s identifiable data or information, please state “Not applicable” under this section.
   Answer: we have added the consent for publication section.

15. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.